Show simple item record

dc.contributor.authorLeta, Tesfaye Hordofa
dc.contributor.authorGjertsen, Jan-Erik
dc.contributor.authorDale, Håvard
dc.contributor.authorHallan, Geir
dc.contributor.authorLygre, Stein Håkon Låstad
dc.contributor.authorFenstad, Anne Marie
dc.contributor.authorDyrhovden, Gro Sævik
dc.contributor.authorWestberg, Marianne
dc.contributor.authorWik, Tina Strømdal
dc.contributor.authorJakobsen, Rune Bruhn
dc.contributor.authorAamodt, Arild
dc.contributor.authorRöhrl, Stephan Maximillian
dc.contributor.authorGøthesen, Øystein Johannes
dc.contributor.authorLindalen, Einar
dc.contributor.authorHeir, Stig
dc.contributor.authorLudvigsen, Jarle
dc.contributor.authorBruun, Trond
dc.contributor.authorHansen, Ann Kristin
dc.contributor.authorAune, Knut Erik Moen
dc.contributor.authorWarholm, Marianne
dc.contributor.authorSkjetne, John Petter
dc.contributor.authorBadawy, Mona
dc.contributor.authorHøvding, Pål
dc.contributor.authorHusby, Otto Schnell
dc.contributor.authorKarlsen, Øystein Espeland
dc.contributor.authorFurnes, Ove Nord
dc.description.abstractIntroduction The current evidence on the efficacy of antibiotic-loaded bone cement (ALBC) in reducing the risk of periprosthetic joint infections (PJI) after primary joint reconstruction is insufficient. In several European countries, the use of ALBC is routine practice unlike in the USA where ALBC use is not approved in low-risk patients. Therefore, we designed a double-blinded pragmatic multicentre register-based randomised controlled non-inferiority trial to investigate the effects of ALBC compared with plain bone cement in primary total knee arthroplasty (TKA). Methods and analysis A minimum of 9,172 patients undergoing full-cemented primary TKA will be recruited and equally randomised into the ALBC group and the plain bone cement group. This trial will be conducted in Norwegian hospitals that routinely perform cemented primary TKA. The primary outcome will be risk of revision surgery due to PJI at 1-year of follow-up. Secondary outcomes will be: risk of revision due to any reason including aseptic loosening at 1, 6, 10 and 20 years of follow-up; patient-related outcome measures like function, pain, satisfaction and health-related quality of life at 1, 6 and 10 years of follow-up; risk of changes in the microbial pattern and resistance profiles of organisms cultured in subsequent revisions at 1, 6, 10 and 20 years of follow-up; cost-effectiveness of routine ALBC versus plain bone cement use in primary TKA. We will use 1:1 randomisation with random permuted blocks and stratify by participating hospitals to randomise patients to receive ALBC or plain bone cement. Inclusion, randomisation and follow-up will be through the Norwegian Arthroplasty Register. Ethics and dissemination The trial was approved by the Western Norway Regional Committees on Medical and Health Research Ethics (reference number: 2019/751/REK vest) on 21 June 2019. The findings of this trial will be disseminated through peer-reviewed publications and conference presentations. Trial registration number NCT04135170.en_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.titleAntibiotic-loaded bone cement in prevention of periprosthetic joint infections in primary total knee arthroplasty: A register-based multicentre randomised controlled non-inferiority trial (ALBA trial)en_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2021 Author(s) (or their employer(s))en_US
dc.source.journalBMJ Openen_US
dc.identifier.citationBMJ Open. 2021, 11 (1), e41096en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse-Ikkekommersiell 4.0 Internasjonal